A Cholesterol Lowering Therapy of Focused Power Ultrasound Mediated Perirenal Fat Ablation

Exclusion Criteria

• •1. Familial hyperlipidemia.
• •2. Participants are taking cholesterol metabolism related drugs (e.g. fibrate drugs, thiazide diuretics, glucocorticoid, para-amino salicylic acid, colchicine, thyroid hormone, thyroid preparation, hypoglycemic, heparin, new oral anticoagulant, chlortetracycline, kanamycin, neomycin).
• •3. Participants are unwilling to stop taking statins.
• •4. Presence of history of hypertension and at least 2 of the following risk factors:
• •* History of smoking (more than 10 years and more than 10 cigarettes per day).
• •* Male ≥ 45 years old, female ≥ 55 years old.
• •* HDL-C≤1 mmol/L.
• •5. Presence of clinical documented atherosclerotic cardiovascular diseases (including acute coronary syndrome, stable angina, coronary revascularization, ischemic cardiomyopathy, stroke, transient cerebral ischemia and peripheral atherosclerosis disease defined as stenosis ≥50% or complex plaques of lower limb arteries, renal arteries, carotid arteries and other peripheral arteries).
• •6. Presence of cardiovascular diseases(e.g. all types of atrial fibrillation; severe structural heart disease including severe pulmonary hypertension resulting from severe aortic or ventricular septal defect, complicated anomaly and severe valvular disease; second degree or above heart block).
• •7. Presence of previous surgery of kidney or pararenal tissue.
• •8. Presence of endocrine-related diseases(e.g. Diabetes, Cushing syndrome, thyroidectomy or thyroid dysfunction in need of drug treatment, primary aldosteronism, Hypofunction of adrenal cortex, Polycystic Ovary Syndrome, Hyperparathyroidism, Insulin tumor, Zollinger-Ellison syndrome).
• •9. Presence of autoimmune diseases (e.g. systemic lupus erythematosus, rheumatoid arthritis, Sjögren syndrome, scleroderma, ulcerative colitis, dermatomyositis, pemphigus, mixed connective tissue disease, sarcoidosis, Takayasu Arteritis).
• •10. Presence of severe hematologic diseases (e.g. leukemia, lymphoma, aplastic anemia, autoimmune hemolytic anemia, multiple myeloma, Primary Immune Thrombocytopenia, thrombotic thrombocytopenic Purpura, abnormal coagulation).
• •11. Presence of infectious diseases (e.g. Hepatitis, tuberculosis, AIDS, syphilis, malaria, measles).
• •12. Presence of parasitic diseases.
• •13. Presence of significant liver dysfunction (ALT or AST elevation greater than 2 times normal upper limit or other evidence of liver injury).
• •14. Presence of significant renal dysfunction (GFR\< 90 mL / min / 1.73 m2 or other evidence of renal injury).
• •15. Presence of urinary calculi and/or hematuria (gross hematuria or occult blood positive).
• •16. Presence of skin infection at the waist.
• •17. Presence of active malignancy.
• •18. Pregnant women or in suckling period or planning for pregnancy in trial period.
• •19. Participants are unwilling to sign an informed consent form.
• •20. Participants are unable or unwilling to complete follow-up evaluations.